Over the past decade, immune checkpoint inhibitors have transformed cancer care for a variety of tumor types. This form of immunotherapy can lead to long-lasting responses in some patients; however, most patients’ cancers do not respond to this therapy, and those that initially respond may develop resistance.
Researchers present new data on cancer biology, treatment, screening and risk reduction at the AACR Virtual Annual Meeting I.
At the AACR Virtual Annual Meeting I, researchers presented data on blood tests that aim to supplement current cancer screening and speed up diagnosis.
A short time after Mallika Lala, PhD, finished her presentation titled “Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients” at the AACR Virtual Annual Meeting I, the U.S. Food and Drug Administration approved the dosing schedule she discussed as a new way to use pembrolizumab (Keytruda) in the treatment of patients with cancer.
Early detection of most cancers is an elusive and daunting task; nevertheless, it has remained a top priority for the cancer research community. Detecting cancer early has manifold advantages: It can increase a patient’s chances of successful treatment, prolong their survival, and substantially improve their quality of life.
Researchers from around the globe share insights into cancer and the coronavirus.
The FDA has approved an alternative dosing schedule for the immune checkpoint inhibitor pembrolizumab.
The FDA approved a new molecularly targeted therapeutic for certain patients with lung cancer driven by a mutation in the MET gene.
While the incidence of melanoma has been rising, the mortality rate has experienced a steep decline over the past few years. This is largely attributable to major advances in treatment during the past two decades, including the development of BRAF...
One in three cancer survivors reports that they or their partners have stayed in jobs due to concerns about keeping health insurance and other cancer news of the week from the staff of Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More